Affinity Investment Advisors’s Halozyme HALO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q1
Sell
-8,886
Closed -$328K 151
2023
Q4
$328K Sell
8,886
-6,820
-43% -$257K 0.22% 139
2023
Q3
$600K Sell
15,706
-480
-3% -$19.7K 0.39% 95
2023
Q2
$584K Sell
16,186
-2,958
-15% -$101K 0.34% 113
2023
Q1
$731K Hold
19,144
0.39% 105
2022
Q4
$1.09M Sell
19,144
-2,757
-13% -$141K 0.5% 64
2022
Q3
$866K Hold
21,901
0.45% 74
2022
Q2
$964K Sell
21,901
-930
-4% -$40.2K 0.47% 62
2022
Q1
$911K Sell
22,831
-680
-3% -$24.2K 0.37% 97
2021
Q4
$945K Sell
23,511
-485
-2% -$18.1K 0.38% 96
2021
Q3
$976K Buy
+23,996
New +$1M 0.44% 74

Other funds holding HALO

Affinity Investment Advisors's HALO Position: Q1 2024 in Review

Affinity Investment Advisors sold out of Halozyme (HALO) in Q1 2024, closing a stake of 8,886 shares — an estimated $328K sold.

Affinity Investment Advisors first reported a position in HALO in Q3 2021 and held it in 10 quarters. The position peaked at $1.09M in Q4 2022. 414 funds tracked by Wall St. Rank hold HALO as of Q1 2024.

  • Affinity Investment Advisors reported no remaining Halozyme position as of Q1 2024 after selling out during the quarter.
  • Affinity Investment Advisors sold 8,886 Halozyme shares in Q1 2024, an estimated $328K.
  • Affinity Investment Advisors first reported a position in Halozyme in Q3 2021 and held it in 10 quarters.
  • Affinity Investment Advisors's Halozyme position peaked at $1.09M in Q4 2022.
  • 414 funds tracked by Wall St. Rank held Halozyme as of Q1 2024.

Based on Affinity Investment Advisors's 13F filing for Q1 2024, filed 3 May 2024.